An Open Label, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs TAK-981 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 25 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Sep 2018 Planned initiation date changed from 15 Sep 2018 to 28 Sep 2018.
- 04 Sep 2018 New trial record